LBPH News and Press, Longboard Pharmaceuticals Inc. From 02/10/23

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its voting common...

Longboard Pharmaceuticals ( NASDAQ: LBPH ) announced underwritten public offering of 5M shares at a price to the public of $4.00 per share. The gross proceeds are expected to be $20M. Underwriters' have a 30-day option to purchase up to an additional 750,000 shares. The of...

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its voting common...

Longboard Pharmaceuticals ( NASDAQ: LBPH ) on Tuesday announced that it has commenced an underwritten public offering to issue and sell $20 million of shares of its voting common stock. Longboard expects to grant the underwriters a 30-day option to purchase up to an additional...

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and s...

LP352 exhibited a strong correlation between plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) concentration, which increased in a dose-dependent and consistent manner LP352 demonstrated early quantitative electroencephalogram (qEEG) changes, and sustained effects on qEEG act...

Presenting data evaluating LP352 engagement of central 5-HT2C receptors via effects on prolactin, and assessing binding activity and functional agonism of LP352 at the 5-HT2 receptors Hosting scientific exhibit highlighting the ongoing Phase 1b/2a PACIFIC Study, and LP352, a...

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Guggen...

Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): Q3 GAAP EPS of -$0.68 misses by $0.11 . At September 30, 2022, Longboard’s cash, cash equivalents and short-term investments were approximately $77.3 million. Our cash position is expected to support oper...

LP352 Phase 1b/2a PACIFIC Study in participants with a range of developmental and epileptic encephalopathies (DEEs) ages 12-65 on track for topline data in second half 2023 Phase 1 open-label study to assess central nervous system (CNS) pharmacokinetics (PK) and pharmacodyna...